- Home
- SLGL vs NRXP Comparison
SLGL vs NRXP Comparison
Compare SLGL & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLGL
- NRXP
- Stock Information
- Founded
- SLGL 1997
- NRXP 2015
- Country
- SLGL Israel
- NRXP United States
- Employees
- SLGL N/A
- NRXP N/A
- Industry
- SLGL Biotechnology: Pharmaceutical Preparations
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- SLGL Health Care
- NRXP Health Care
- Exchange
- SLGL Nasdaq
- NRXP Nasdaq
- Market Cap
- SLGL 18.3M
- NRXP 14.8M
- IPO Year
- SLGL 2018
- NRXP N/A
- Fundamental
- Price
- SLGL $0.52
- NRXP $1.27
- Analyst Decision
- SLGL Strong Buy
- NRXP Strong Buy
- Analyst Count
- SLGL 2
- NRXP 3
- Target Price
- SLGL $5.00
- NRXP $31.33
- AVG Volume (30 Days)
- SLGL 68.5K
- NRXP 160.5K
- Earning Date
- SLGL 11-15-2024
- NRXP 11-14-2024
- Dividend Yield
- SLGL N/A
- NRXP N/A
- EPS Growth
- SLGL N/A
- NRXP N/A
- EPS
- SLGL N/A
- NRXP N/A
- Revenue
- SLGL $11,707,000.00
- NRXP N/A
- Revenue This Year
- SLGL $457.85
- NRXP N/A
- Revenue Next Year
- SLGL N/A
- NRXP N/A
- P/E Ratio
- SLGL N/A
- NRXP N/A
- Revenue Growth
- SLGL 869.93
- NRXP N/A
- 52 Week Low
- SLGL $0.33
- NRXP $1.10
- 52 Week High
- SLGL $1.58
- NRXP $7.33
- Technical
- Relative Strength Index (RSI)
- SLGL 37.57
- NRXP 43.63
- Support Level
- SLGL $0.40
- NRXP $1.13
- Resistance Level
- SLGL $0.57
- NRXP $1.36
- Average True Range (ATR)
- SLGL 0.06
- NRXP 0.09
- MACD
- SLGL -0.01
- NRXP 0.01
- Stochastic Oscillator
- SLGL 36.50
- NRXP 34.37
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline consists of silica-based microencapsulation technology platform, and several generic product candidates across multiple indications.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.